The M-L233 antibody reacts with the low affinity receptor for human IgE, FcεRII/CD23. CD23 is a type II membrane protein which can be expressed by B cells, monocytes, macrophages, eosinophils, platelets, and dendritic cells. CD23 can mediate IgE-dependent cytotoxicity and phagocytosis by macrophages and eosinophils. Soluble CD23 (sCD23) can be released by CD23+ cells as a result of proteolytic cleavage of membrane CD23. Larger fragments of sCD23 (e.g., 37-25 kDa) retain their IgE-binding capacity whereas smaller fragments (i.e., ≤ 12 kDa) do not. Soluble CD23 may have immunoregulatory effects on the growth and differentiation of B cells and other cell types. Profile of peripheral blood lymphocytes analyzed on a FACScan
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C
Storage Comment
Store undiluted at 4°C.
Saeland, Duvert, Moreau, Banchereau: "Human B cell precursors proliferate and express CD23 after CD40 ligation." in: The Journal of experimental medicine, Vol. 178, Issue 1, pp. 113-20, (1993) (PubMed).
Delespesse, Hofstetter, Sarfati: "Low-affinity receptor for IgE (FcERII, CD23) and its soluble fragments." in: International archives of allergy and applied immunology, Vol. 90 Suppl 1, pp. 41-4, (1990) (PubMed).
Gordon, Millsum, Flores-Romo, Gillis: "Regulation of resting and cycling human B lymphocytes via surface IgM and the accessory molecules interleukin-4, CD23 and CD40." in: Immunology, Vol. 68, Issue 4, pp. 526-31, (1990) (PubMed).
Target
FCER2
(Fc Fragment of IgE, Low Affinity II, Receptor For (CD23) (FCER2))